Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab

BACKGROUND: Long-term data on inflammatory bowel disease (IBD) patients switched from originator to biosimilar infliximab SB2 are lacking. The aim of the conducted study was to investigate the effectiveness, immunogenicity and safety of a large prospectively followed-up IBD patient cohort that was e...

Descripción completa

Detalles Bibliográficos
Autores principales: Fischer, Sarah, Cohnen, Sarah, Klenske, Entcho, Schmitt, Heike, Vitali, Francesco, Hirschmann, Simon, Ramming, Andreas, Zundler, Sebastian, Rath, Timo, Krebs, Sabine, Dörje, Frank, Uter, Wolfgang, Nagore, Daniel, Meyer, Sebastian, Neurath, Markus F., Atreya, Raja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812413/
https://www.ncbi.nlm.nih.gov/pubmed/33505519
http://dx.doi.org/10.1177/1756284820982802

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812413/
https://www.ncbi.nlm.nih.gov/pubmed/33505519
http://dx.doi.org/10.1177/1756284820982802

Ejemplares similares